Health Care & Life Sciences » Pharmaceuticals | Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
317.00
3,620.00
24,033.00
18,473.00
18,954
Other Current Assets
13.00
23.00
713.00
515.00
732
Total Current Assets
330.00
3,643.00
24,746.00
18,988.00
19,686
Other Assets
-
847.00
8.00
29.00
8
Total Assets
348.00
4,490.00
24,754.00
19,017.00
19,694
ST Debt & Current Portion LT Debt
737.00
6,424.00
-
1,355.00
Accounts Payable
-
-
-
4,025.00
Income Tax Payable
18.00
-
-
-
Other Current Liabilities
124.00
2,493.00
4,121.00
1,010.00
Total Current Liabilities
879.00
8,917.00
4,121.00
6,390.00
Long-Term Debt
-
-
-
8,683.00
Deferred Taxes
18.00
-
-
-
Other Liabilities
-
-
1.00
3.00
Total Liabilities
879.00
8,917.00
4,122.00
15,076.00
Common Equity (Total)
531.00
12,380.00
20,632.00
3,941.00
Total Shareholders' Equity
531.00
4,427.00
20,632.00
3,941.00
Total Equity
531.00
4,427.00
20,632.00
3,941.00
Liabilities & Shareholders' Equity
348.00
4,490.00
24,754.00
19,017.00
Preferred Stock (Carrying Value)
-
7,953.00
-
-

About Gemphire Therapeutics

View Profile
Address
17199 North Laurel Park Drive
Livonia Michigan 48152
United States
Employees -
Website http://www.gemphire.com
Updated 07/08/2019
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.